Thin
1 / 1
Mots-c is a short peptide composed of 16 amino acids, and its encoding gene is located on mitochondrial DNA. This discovery challenges the conventional wisdom that mitochondrial DNA only encodes respiratory chain-related proteins.
Main function: The core function of Mots-c is as a regulator of cellular metabolism, particularly in glucose metabolism and insulin sensitivity. It mimics some of the effects of exercise and is therefore also known as a "motor-mimicking peptide".
Mechanism of action: It primarily functions by activating the AMPK pathway, a key energy sensor within cells. This promotes glucose uptake by cells, improves insulin sensitivity, and influences fatty acid metabolism.
Based on its powerful metabolic regulation capabilities, research on Mots-c mainly focuses on the following therapeutic areas:
This is Mots-c's core research focus. It can significantly improve insulin resistance and lower blood sugar, and has the potential to become a novel antidiabetic drug.
Mots-c can promote energy expenditure, reduce fat accumulation, and induce the conversion of white fat into brown fat-like fat (thermogenesis), thereby helping to control weight.
Mots-c can improve age-related metabolic decline, enhance the cells' resistance to stress, and has shown the potential to extend healthy lifespan in animal experiments.
By improving metabolism and promoting muscle health, it may help combat muscle loss caused by age or disease.
Preliminary studies suggest it may have a protective effect against diseases such as Alzheimer's, mainly by improving brain cell energy metabolism and reducing oxidative stress.
As a "sports simulator," it has been explored for its use in enhancing physical fitness, improving exercise endurance, and accelerating post-exercise recovery.
Cardiovascular protection, non-alcoholic fatty liver disease, and other diseases closely related to metabolic disorders.
Mots-c has a promising future, but it is still in the critical stage of translating from basic research to clinical application.
As the first mitochondrial-derived peptide to be extensively studied, it opens up a completely new path for drug development and has huge market potential.
It targets the common core of aging and metabolic diseases—the imbalance of cellular energy metabolism—and therefore may have multiple benefits.
Suggests a treatment option that mimics the benefits of exercise for people who are unable to exercise enough (such as the elderly and those with mobility impairments), with clear market demand.
Currently, the vast majority of data comes from preclinical studies (cell and animal experiments). Advancing to human clinical trials is the biggest challenge and the most critical step.
As a peptide, it is easily degraded, and issues such as administration route (e.g., low oral bioavailability, usually requiring injection) and stability need to be addressed.
The long-term effects, optimal dosage, and potential side effects in humans require further investigation.
Synthesizing or producing this peptide on a large scale and with high quality, and obtaining approval from drug regulatory agencies (such as FDA and NMPA), is necessary for industrialization.
Mots-c is encoded within the mitochondrial DNA rather than nuclear DNA, breaking the traditional view that mitochondrial DNA only encodes respiratory chain proteins. It functions centrally as a hormonal regulator of systemic cellular energy and metabolism.
It triggers physiological responses similar to exercise by activating the cellular AMPK pathway. This enhances insulin sensitivity, promotes cellular glucose uptake, and aids in body weight and fat regulation.
No, Mots-c is primarily in the preclinical research stage. Extensive clinical trials are still required before regulatory bodies like the FDA or NMPA can grant approval for standard medical use.
By addressing the decline in cellular energy metabolism, Mots-c improves cellular stress resistance, combats muscle loss (sarcopenia), and supports healthy metabolic function typically degraded by the aging process.
Because it is a 16-amino acid peptide, it is prone to enzymatic degradation and has very low oral bioavailability, usually requiring delivery methods like injection alongside formulation enhancements to improve stability.
